RBC Europe’s Ionis Pharmaceuticals IONS Stock Holding History

RBC Europe’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-150	Closed	-$8.48K	–	1212
2020 Q4	$8.48K	Hold	150	–	–	﹤0.01%	903
2020 Q3	$7.12K	Hold	150	–	–	﹤0.01%	860
2020 Q2	$8.84K	Hold	150	–	–	﹤0.01%	793
2020 Q1	$7.09K	Hold	150	–	–	﹤0.01%	769
2019 Q4	$9.06K	Hold	150	–	–	﹤0.01%	820
2019 Q3	$8.99K	Hold	150	–	–	﹤0.01%	808
2019 Q2	$9.64K	Hold	150	–	–	﹤0.01%	807
2019 Q1	$12.2K	Hold	150	–	–	﹤0.01%	773
2018 Q4	$8.11K	Hold	150	–	–	﹤0.01%	839
2018 Q3	$7.74K	Hold	150	–	–	﹤0.01%	893
2018 Q2	$6.25K	Hold	150	–	–	﹤0.01%	934
2018 Q1	$6.61K	Hold	150	–	–	﹤0.01%	912
2017 Q4	$7.54K	Buy	+150	New	+$8.23K	﹤0.01%	884

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RBC Europe's IONS Position: Q1 2021 in Review

RBC Europe sold out of Ionis Pharmaceuticals (IONS) in Q1 2021, closing a stake of 150 shares — an estimated $8.48K sold.

RBC Europe first reported a position in IONS in Q4 2017 and held it in 13 quarters. The position peaked at $12.2K in Q1 2019. 364 funds tracked by Wall St. Rank hold IONS as of Q1 2021.

RBC Europe reported no remaining Ionis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
RBC Europe sold 150 Ionis Pharmaceuticals shares in Q1 2021, an estimated $8.48K.
RBC Europe first reported a position in Ionis Pharmaceuticals in Q4 2017 and held it in 13 quarters.
RBC Europe's Ionis Pharmaceuticals position peaked at $12.2K in Q1 2019.
364 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.